WO2006060049A2 - Method and apparatus for reducing obesity - Google Patents

Method and apparatus for reducing obesity Download PDF

Info

Publication number
WO2006060049A2
WO2006060049A2 PCT/US2005/029932 US2005029932W WO2006060049A2 WO 2006060049 A2 WO2006060049 A2 WO 2006060049A2 US 2005029932 W US2005029932 W US 2005029932W WO 2006060049 A2 WO2006060049 A2 WO 2006060049A2
Authority
WO
WIPO (PCT)
Prior art keywords
flow reduction
duodenal
elongated member
reduction element
small intestinal
Prior art date
Application number
PCT/US2005/029932
Other languages
French (fr)
Other versions
WO2006060049A3 (en
Inventor
Kenneth Binmoeller
Original Assignee
Kenneth Binmoeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Binmoeller filed Critical Kenneth Binmoeller
Priority to PL05791635T priority Critical patent/PL1817072T3/en
Priority to CA2588901A priority patent/CA2588901C/en
Priority to BRPI0518726-5A priority patent/BRPI0518726A2/en
Priority to MX2007006419A priority patent/MX2007006419A/en
Priority to EP05791635A priority patent/EP1817072B1/en
Priority to JP2007544333A priority patent/JP2008521550A/en
Priority to ES05791635T priority patent/ES2416295T3/en
Publication of WO2006060049A2 publication Critical patent/WO2006060049A2/en
Publication of WO2006060049A3 publication Critical patent/WO2006060049A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • A61F5/003Implantable devices or invasive measures inflatable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • A61F5/0036Intragastrical devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • A61F5/0076Implantable devices or invasive measures preventing normal digestion, e.g. Bariatric or gastric sleeves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013Implantable devices or invasive measures
    • A61F5/0076Implantable devices or invasive measures preventing normal digestion, e.g. Bariatric or gastric sleeves
    • A61F5/0079Pyloric or esophageal obstructions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/02Holding devices, e.g. on the body
    • A61M25/04Holding devices, e.g. on the body in the body, e.g. expansible
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2002/045Stomach, intestines

Definitions

  • the present invention relates to the medical treatment of obesity in humans, and more particularly to apparatus and methods for curbing the appetite of persons being treated for obesity.
  • Extreme obesity is a major health concern in the United States and other countries. Its complications may include hypertension, diabetes, coronary artery disease, stroke, congestive heart failure, venous disease, multiple orthopedic problems and pulmonary insufficiency with markedly decreased life expectancy. Medical management including dietary, psychotherapy, medications and behavioral modification techniques have not yielded exceptional results in multiple trials. Despite the declaration of obesity as a major health problem, the Centers for Disease Control reports that obesity contributes to about 400,000 deaths annually, just behind tobacco (435,000) and ahead of alcohol (85,000), car accidents (43,000) and guns (29,000). Obesity and its complications now account for an estimated 9 percent of U.S. health spending.
  • Non-surgical approaches for the treatment of obesity include voluntary dieting which is often unsuccessful since most persons do not possess sufficient willpower to limit the intake of food.
  • several surgical techniques have been tried which induce malabsorption by reducing the absorptive surface of the small intestine or modify the stomach to reduce a patients desire to eat.
  • Gastric reduction surgeries in which the stomach's volume is reduced had limited early success but often the stomach's size stretches over time so these patients did not exhibit real weight for a sustained period of time.
  • Other surgical approaches combine gastric volume reduction by either partition or bypass with a reduction in the absorptive surface of the small intestine.
  • These procedures may be both hazardous to perform in morbidly obese patients and often create numerous life- threatening postoperative complications. Such procedures typically are invasive, require a long recuperation time and subject the patient to undue pain and discomfort. Also, such operative procedures are often difficult to reverse. These procedures are also expensive and place a large burden on the national health care system.
  • the present invention further recognizes a need for a transoral endoscopic device that mediates physiologic weight loss that is easily inserted into and removed from the gastrointestinal tract, well tolerated by the patient, does not migrate, does not adversely obstruct the lumen, and does not cause tissue injury.
  • the present invention provides a method and apparatus for treatment of morbid obesity by placement of a series of flow reduction elements in the small intestine to induce satiety.
  • the flow reduction elements are attached along an elongated member which may or may not have a central lumen inside. This elongated member is used to position the flow reduction elements in the small intestine.
  • the length and diameter of the flow reduction section can be selected by the physician to adjust the amount of weight reduction to the patients needs.
  • the central tube has an anchoring member attached near the proximal end that secures the proximal end in the antrum of the stomach.
  • the anchoring member is sized so that it will not pass through the pyloric valve and so that it secures the central tube and the attached flow reduction elements in proper position in the small intestine.
  • the anchoring member is constructed of one or more inflatable balloons that when inflated are larger than the pylorus. The anchoring balloons can be deflated for delivery into the stomach and removed through the working lumen or alongside an endoscope.
  • the anchoring member is an expandable umbrella-like skeleton frame that is attached to the flexible tube. The large end of the umbrella faces the pylorus and the frame can be collapsed for delivery and recovery.
  • the flow reduction elements can have various shapes and may be attached at various points along the central tube.
  • the flow reduction elements may be inflated with fluid through a fluid connection with the central tube or may be constructed from self-expandable material such as a foam or spring structure.
  • the space occupying flow reduction elements may also be filled or impregnated with pharmacologies, biochemicals, alimentary lipids, alimentary peptides or metabolic substances that release into the small intestine to further provide feelings of satiety.
  • the transoral gastric device can be inserted with a delivery catheter through the working lumen of an endoscope or alongside an endoscope and may be removed with the aid of an endoscope if desired.
  • FIG. 1 is a general drawing of the stomach and adjacent parts of the alimentary canal.
  • FIG. 2 is a perspective view of a duodenal/small intestinal insert in accordance with the present invention positioned inside the stomach and small intestine.
  • FIG. 3 is a partial section view of a central tube illustrating attached flow reduction elements and central lumen.
  • FIG. 4 is a partial section view of a central tube illustrating eccentrically attached flow reduction elements and central lumen.
  • FIG. 5 is a perspective view of an alternative embodiment showing an elongated member and illustrating attached flow reduction elements.
  • FIG. 6 is a section view of the central tube inside of the pylorus and small intestine.
  • FIG 7 is a perspective section view of a central tube and an anchoring member.
  • FIG. 8 is a perspective view of an alternative embodiment of a central tube and an anchoring member.
  • FIG. 9a is a section view of alternative embodiment of the current invention.
  • FIG. 9b is a section view of alternative embodiment of the current invention shown in a collapsed configuration.
  • FIG. 1 shows the human stomach and small intestine. Important features are the esophagus 2, stomach 4, antrum 7, pylorus 8, pyloric valve 11, duodenum 10, jejunum 12 and ampulla of Vater 13.
  • the esophagus 2 terminates at the nose or mouth at its superior end and at the stomach 4 at its inferior end.
  • the stomach 4 encloses a chamber which is characterized, in part, by the esophageal-gastric juncture 6, which is an opening from the esophagus 2 at one end, and the antrum-pyloric juncture 5 which is a passageway between the antrum 7 through the pylorus 8 to the duodenum 10 at the other end.
  • the pylorus 8 controls discharge from the stomach 4 by a sphincter muscle, the pyloric valve 11, which enables the pylorus 8 to open wide enough to pass an object which is approximately one cubic centimeter or less.
  • Gastric contents after passing into the duodenum 10, continue on into the jejunum 12 and on into the ileum (not shown).
  • the duodenum 10, jejunum 12 and ileum make up what is known as the small intestine.
  • these individual portions of the alimentary canal are sometimes individually referred to as the small intestine.
  • the small intestine refers to all or part of the duodenum, jejunum and ileum.
  • the ampulla of Vater 13 is shown as a small protrusion on the medial wall. Bile and pancreatic fluids enter the duodenum 10 at this point to further aid digestion.
  • the duodenum 10 comprises the first nine to ten inches of the small intestine and is the only portion of the small intestine which is attached to the back wall of the abdominal cavity (retroperitoneum). The remainder of the small intestine is not attached to the body, but merely folds freely in a sack called the mesentery, which is contained within the peritoneum.
  • the digestive process starts when food materials are mixed with saliva and enzymes in the mouth. The digestive process continues in the stomach 4, where the food is combined with acids and additional enzymes to liquefy the food.
  • This food resides in the stomach 4, for a short time and then it passes into the duodenum 10 to be intermixed with bile and pancreatic juice, which make the nutrients contained therein available for absorption by the villi and microvilli of the small intestine or by other absorptive organs of the body.
  • the present invention understands that if the passage of partially digested food as described is partially blocked and the flow rate through the small intestine is reduced, then the emptying of the stomach and the duodenum will occur slower. This in turn will create a feeling of satiety and will decrease the consumption of food by an obese patient.
  • the partially digested food materials are not readily absorbed by the small intestine or other absorptive organs of the body.
  • the partially digested food materials are then passed to the large intestine for elimination from the body with limited caloric absorption by the body.
  • the present invention understands that if the physical characteristics of the device and/or a reduction of flow rate of food breakdown products through the small intestine results in distension of the small intestine, or increases the contact time between the small intestine and the partially digested food then this distention or increased contact time may activate osmoreceptors that may release hormones and neurotransmitters such as cholecystokinins (CCK) and neural signals that may induce satiety.
  • CCK cholecystokinins
  • Figure 2 shows an exemplary non-limiting small intestinal insert 20 made in accordance with the present invention in position in the stomach and small intestine.
  • the insert has a proximal portion 30 and a distal portion 40.
  • the insert has a central tube 50 that extends between the proximal portion 30 and the distal portion 40.
  • a series of flow reduction elements 200 can be attached to the distal portion of the central tube and may be sized to fit inside the small intestine. However the area of the central tube 50 near the ampulla of Vater 13 has no flow reduction elements 200 to prevent blockage of the ampulla of Vater.
  • the central tube preferably has an anchoring member 100 attached near a proximal end 52 of the central tube 50, with the anchoring member 100 securing the proximal end 52 of the central tube 50 in the antrum 7 of the stomach.
  • the anchoring member 100 is sized so that it will not pass through the pylorus 8, so that it can maintain the flow reduction elements 200 in proper position in the small intestine.
  • the anchoring member can be established by one or more inflatable balloons 102 that when inflated are larger than the pylorus 8.
  • the inflatable balloons 102 can be deflated for delivery into the stomach and then inflated inside the stomach.
  • the inflatable balloons 102 can also be later deflated for removal using endoscopic techniques.
  • FIG. 3 shows the central tube 50 with the flow reduction elements 200 attached.
  • the central tube 50 can be flexible and constructed of polymeric material that can be easily formed or extruded and delivered with the aid of an endoscope by known techniques.
  • a central tube 50 that is soft and flexible will contour to the anatomy of the gastrointestinal tract and provide less irritation of the stomach lining.
  • the central tube 50 can be made from polymers such as but not limited to nylon, polyolefins, polyurethane, silicone, polyvinyl chloride (PVC), Dacron®, latex, polyethylene, polypropylene, PVCD, polyethylene terephthalate (PET), teflon, and their mixtures and blocks or random copolymers .
  • the central tube may have a mono-layer, bi-layer or multi-layer construction.
  • the central tube may have an inner layer of nylon or ethyl vinyl acetate and an outer layer of silicone for better biocompatibility.
  • the substantially liquid-impermeable material could contain a radiopaque substance to enable visualization of the central tube in the patient's small intestine.
  • the central tube could have band of radiopaque material like a metal foil around its circumference to enable visualization.
  • the central tube polymer needs to be compatible with the chemical environment of the gastrointestinal tract and should provide enough structural integrity to prevent migration of the flow reduction elements in response to peristaltic action in the bowel.
  • the central tube 50 can deploy to a fixed configuration so that once properly positioned it will maintain a steady position despite peristaltic movement of the stomach and small intestine.
  • the fixed configuration could be the shape that the duodenum 10 and jejunuml2 naturally assume in the abdomen.
  • the length of the central tube 50 can be established depending on the therapeutic result desired and the patient's anatomy.
  • the central tube 50 and the attached flow reduction elements 200 may extend into a portion of or through the entire duodenum 10. On some patients the central tube 50 and the attached flow reduction elements 200 may extend past the duodenum 10 and into the jejunum 12. It is anticipated that several lengths might be used by a physician to treat the various body types and metabolic demands. For example, if a patient is 20% overweight, the physician might select a length of central tube 50 with its attached flow reduction elements 200 that permits absorption of only 80% of the nutritional potential of a typical daily intake of calories. The reduction of caloric intake over time will lead to weight loss.
  • Figure 3 shows a central tube 50 with an outer wall 54 and an inner wall 56 that define an interior space 58.
  • the interior space 58 forms an inner lumen 59 that may be continuous from the proximal end 52 to just short of the distal end 53 of the central tube 50.
  • the distal end 53 of the central tube 50 is sealed at a point 55 so that fluid introduced into the central tube 50 does not leak out distally into the small intestine.
  • a valve 90 can be located substantially at the proximal end of the inner lumen 59.
  • the valve 90 may be a self sealing valve that has a septum 92 that can be accessed by a needle or blunt tip tube for introduction of fluid into the inner lumen 59.
  • the valve 90 also can be accessed so that the fluid inside the inner lumen 59 of the central tube 50 can be aspirated for removal. It is to be understood that the valve type is not limited to a septum type valve only, and that other types of mechanical valves may also be used in place of the septum valve described.
  • each flow reduction element 200 can be attached to the central tube 50.
  • the diameter of each flow reduction element 200 can be concentric with the axis of the central tube 50.
  • Each flow reduction element 200 has an outer wall 210, an inner wall 212, and an inner space 214 is established inside the inner wall 212.
  • each flow reduction element 200 can be attached to the central tube 50 with the inner space 214 of the flow reduction element 200 in fluid communication with the lumen 59 of the central tube 50, such that the inner space 214 surrounds the outer wall 54 of the central tube 50.
  • Each flow reduction element 200 may be attached to the central tube 50 by adhesives, heat bonding, mechanical restraint or other suitable methods.
  • the central tube 50 can be formed with plural inlet/exit ports 216 that are located inside respective flow reduction elements 200. More specifically, each port 216 is formed completely through the central tube wall 51 to establish a pathway for fluid communication between the inner lumen 59 of the central tube 50 and the inner space 214 of the respective flow reduction element 200. Consequently, the inner lumen 59 of the central tube 50 may be used to introduce fluid into the inner spaces 214 of the flow reduction elements 200 and to inflate the flow reduction elements 200 from a collapsed configuration, in which insertion and removal of the flow reduction elements 200 is facilitated, to an inflated configuration shown in Figure 3, in which resistance to food passage is increased to induce satiety.
  • the flow reduction element or elements 200 in this embodiment act as balloons that can be deflated and collapsed around the central tube 50 for introduction into the small intestine and then inflated to the desired diameter once in position.
  • Each flow reduction element or elements 200 can either be elastic balloons or inelastic balloons.
  • the balloon may be a elastic balloon formed of latex, polyurethane, polyethylene, polypropylene, PVC, PVCD, polyethylene terephthalate (PET), teflon, their mixtures and blocks or random copolymers may also be used, for example.
  • the material may be non-elastic or semi-elastic, such as Dacron®, Nylon®, and the like. It may alternatively be a inelastic balloon formed of polyethylene. Further, the balloon may have a mono-layer, bi-layer or multi-layer construction.
  • the balloon may have an inner layer of nylon or ethyl vinyl acetate and an outer layer of silicone for better biocompatibility.
  • the substantially liquid-impermeable material could contain a radiopaque substance to enable visualization of the balloon in the patient's small intestine.
  • the central tube could have band of radiopaque material like a metal foil around its circumference to enable visualization.
  • an alternate embodiment consisting of an inelastic balloon inflates to a diameter that is independent of the volume of fluid introduced into the inner space of the sphere.
  • the diameter of this type of balloon is fixed when manufactured and does not permit in situ adjustment of the balloon size.
  • this type of balloon prevents possible over inflation and rupture if too much fluid is introduced into the balloon.
  • the flow reduction elements 200 shown in Figure 3 have the shape of a round sphere. However, other shapes are contemplated and any shape that effectively functions to inhibit the passage of partially digested food into the small intestine is acceptable. It is understood that the ability of the small intestinal insert 20 to remain within the small intestine can be affected by the shape, orientation and tautness of the flow reduction elements 200. For example alternate shapes such as ovoid, elliptical, elongated ellipse and even irregular non- geometrical shapes are potentially feasible.
  • Figure 4 illustrates an alternative embodiment of the present invention in which one or more flow reduction elements 300 are eccentrically attached to a central tube 350.
  • the axis or diameter of the flow reduction element or elements 300 is not concentric with the axis of the central tube.
  • the outer wall 302 of the flow reduction element is attached to the side of an outer wall 354 of the central tube 350.
  • An inner space 314 of each flow reduction element 300 is eccentric relative to the axis of the central tube 350 and is in fluid communication with an inner lumen 359 of the central tube 350 through a respective opening 316.
  • the inner lumen 359 can be used to introduce and remove fluid into the inner space 314 of the flow reduction element 300 to move the flow reduction element 300 between inflated and collapsed configurations.
  • the flow reduction elements 300 can be inflated with a fluid, either liquid or gas.
  • the gas is air, nitrogen or carbon dioxide and the liquid is preferably water or water mixed with other solutions, such as sterile saline. It is important for the physician to monitor the flow reduction element 300 location in the small intestine and the diameter of the flow reduction element relative to the diameter of the small intestine.
  • the flow reduction element can be inflated with a radiopaque fluid that is visible on X-ray. If the flow reduction element containing the radiopaque fluid is visible on x-ray, the physician can non-invasively visualize the flow reduction element size from outside the patient's body.
  • radiopaque marker bands 218 as shown in Figure 4 can be placed around the central tubes 50 and 350 respectfully to facilitate visualization of the central tube's location in the small intestine.
  • the radiopaque marker bands 218 can be placed at predetermined intervals so that the distance inside the small intestine can be used as depth markers and can be measured from outside the body, and can be created by tantulum impregnated ink, or tantulum bands.
  • Figure 5 shows an alternative embodiment with a central shaft 450 around ⁇ vhich first flow reduction elements 400 are concentrically attached and second flow reduction elements 410 are eccentrically attached.
  • the element 400 can be attached to the central shaft 450 in any manner as described previously.
  • the flow reduction elements 400 are made from material that can be folded or collapsed to a first volume suitable for insertion with the aid of an endoscope and then self expand to a second volume suitable for restricting the flow of partially digested food according to the present invention.
  • the flow reduction elements can be made from materials such as sponge, foam, hydrogels or springs.
  • the sponge can be composed of polyvinyl acetal polymer, neoprene, silicon
  • the foam can be composed of polyvinyl acetal polymer
  • the hydrogel can include any of the following: polysaccharides, proteins, polyphosphazenes, poly(oxyethylene)-poly(oxypropylene) block polymers, poly(oxyethylene)-poly(oxypropylene) block polymers of ethylene diamine, poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, polyvinyl acetate), and sulfonated polymers. These materials can be compacted into a small volume and then self expand to a pre-determined shape and volume when unrestricted.
  • the central shaft 450 can be solid and without an inner lumen or inner space. Because the flow reduction elements self expand, the need for an inflation system is eliminated and this embodiment represents a simple mechanical design, flow reduction elements are attached mechanically, by heat fusing, adhesives or other suitable methods as known in the art.
  • the surface of the flow reduction element 415 and outside walls of the central tube 452 may be associated with slow release medicaments, enzymes, cofactors, pharmacologies, biochemicals, alimentary lipids, alimentary peptides or metabolic substances.
  • "associated with” means filled or coated, covalently bonded, hydrogen-bonded, layered, impregnated, incorporated into matrices, and other such methods of associating molecules, which will be well-known to one of skill in the art. These substances are designed to release over time into the intestine to modify the biochemical processes or trigger alternative receptor sites that in turn will alter the digestive process.
  • lipase-inhibitors such as orlistat (Xenical®); oradrenergic/serotonergic agents such as sibutramine (Meridia®, Reductil®); anti-depressants such as fluoxetine (Prozac®) and sertraline (Zoloft®), bupropion, (Amfebutamone®, Wellbutrin® and Zyban®); noradrenergic agents/amphetamines such as diethylpropion (Tenuate®, Tepanil®), diethylpropion ER (Tenuate Dospan®), and phentermine (Adipex-P®, Fastin®, Obestin-30®, Phentamine®, Zantryl®; Lonamin®, Oby-Cap®); anti-epileptic drugs such as Topiramate® and Zonisamide®, sympathomimetic amines such as phendimetrazine tatrate (Bontril)
  • Figure 6 shows the central tube 50 in the antrum 7, pylorus 8 and the duodenum 10; consisting of three parts, the duodenal bulb 1OA, the vertical duodenum 1OB, and the horizontal duodenum 1OC.
  • the flow reduction elements have been removed from Figure 6 for clarity.
  • the central tube 50 is shown traversing the pyloric valve 11. It is important that the diameter of the central tube not obstruct the pyloric valve opening so that the valve can still function normally.
  • the central tube diameter should be in the range of 5 to 7 French.
  • the central tube 50 can assume a sharp bend of radius ⁇ between the duodenal bulb 1OA and the vertical duodenum 1OB , and a sharp bend of radius ⁇ between the vertical duodenum 1OB and horizontal duodenum 1OC.
  • the radius ⁇ and the radius ⁇ may be between about 45° and about 110°. More preferably, the radius ⁇ and the radius ⁇ may be between about 60° and about 100° such that the central tube 50 bends to follow the inner lumen of the duodenum 10 at this these locations. It is advantageous that the central tube 50 be flexible enough to conform to this sharp angulation to avoid kinking.
  • the central tube 50 can be pre-formed with a configuration that conforms to the duodenal angulations prior to insertion in the body and is constrained in a straight configuration by a stiffening rod 110 placed down the inner lumen 59 of the central tube 50 as shown.
  • This stiffening rod 110 is placed into a separate lumen designed to house this stiffening rod or imbedded in the wall of the central tube 50.
  • the central tube 50 may have a shape memory alloy wire imbedded inside the central tube wall 51 or residing in the inner lumen 59.
  • This shape memory alloy wire has a pre-set bend configuration with a radius ⁇ and a radius ⁇ that matches the bend configuration of the duodenum and is positioned in the central tube 50 at the corresponding location.
  • Shape memory alloy wire can be composed metal alloys, including but not limited to, NiTi (Nickel - Titanium), CuZnAl, and CuAlNi.
  • the central tube 50 may have a spring embedded inside the central tube wall 51 or inner lumen 59. This spring could be pre-shaped to the anatomy of the wall of the small intestine. The spring is held straight during delivery and conforms to the small intestine anatomy after release. The shape enables the device to remain in place.
  • the central tube 50 has an anchoring member 100 attached near the proximal end 52.
  • the anchoring member 100 can be established by one or more inflatable balloons 102. These balloons 102 can be eccentrically attached to the central tube at point 104 near the proximal end 52 of the central tube 50. These balloons can be formed in many shapes and are not limited to the spherical shape shown.
  • the central tube can be formed with an opening 116 for each respective balloon 102 so that a pathway for fluid communication is established between the inner lumen 59 of the central tube 50 and the inner space of each balloon 106.
  • the inner lumen 59 is used to introduce fluid into the inner space of the balloon 106 and inflate the balloon 102 from a first volume in a collapsed state to a second volume or inflated state.
  • the inflatable balloons 102 have a combined cross sectional diameter greater than the diameter of the pyloric valve 11 to prevent migration across the pylorus 8.
  • the inflatable balloons 102 can be inflated and deflated by adding or removing fluid from the central tube inner lumen 59.
  • the inflatable balloons 102 may be connected to the same central tube inner lumen 59 as flow reduction elements 200 and 300 as shown in Figures 3 and 4, and can be inflated simultaneously and deflated simultaneously.
  • the central tube 50 may have more than one inner lumen so that the inflatable balloons 102 and individual flow reduction elements 200 and 300 may be inflated and deflated independently from each other.
  • Figure 8 illustrates another embodiment of the anchoring member 100 deployed in the antrum 7.
  • a central tube 50 is attached to an inverted umbrella skeleton 160.
  • This skeleton 160 has a ring 162 that surrounds the central tube 50 and is supported by three struts 164, 165 and 166. These struts are joined together at the central tube 50 at point 167 and attached to the ring 162 at points 170, 171 and 172.
  • three struts are illustrated in Figure 8, it is possible to construct the anchoring member 100 with one or more struts.
  • the ring 162 is made from flexible plastic material or flexible wire and has a diameter significantly larger than the diameter of the pyloric valve 11.
  • the umbrella skeleton 160 is collapsed around the central tube 50 for insertion into the stomach with the aid of an endoscope. As the device is released from the endoscope, the umbrella skeleton 160 springs out and assumes a configuration shown in Figure 8.
  • the struts 164, 165 and 166 may be made from plastic, metal or from plastic covered metal.
  • the edge of the ring 162 which is in contact with the antrum walls 163, may be constructed to assist in securing the umbrella ring 162 to the walls of the antrum.
  • the surface of the ring may be roughened to increase surface friction or the wall may have protrusions or barbs that physically attach to the stomach lining.
  • Figure 9 illustrates another embodiment of the current invention.
  • Figure 9a depicts a duodenal/small intestinal insert 500 with a proximal portion 502 and a distal portion 504 shown in an expanded state.
  • a central shaft 506 is attached to an expandable sleeve 508 at the sleeve distal end 510 near the distal portion 504 of the duodenal/small intestinal insert.
  • the opposite end of the central shaft 506 is attached to a toroid anchoring member 520.
  • the anchoring member 520 is attached at the central shaft 506 with two connecting struts 521 and 522. More than two connecting struts may be employed to securely attach the toroid anchoring member 520 to the central shaft 506.
  • the anchoring member 520 is shaped like a funnel that is designed to seat in the Pylorus without obstructing its function.
  • the central shaft 506 may be pre-formed to have a configuration that conforms to the anatomy of the duodenum 10 shown in Figure 6. A central shaft 506 so described would also force the expandable sleeve 508 to assume the configuration of the shaft 506.
  • the central shaft 506 may be constructed out of wire, spring, shape memory alloys, hollow steel tubing or plastic polymers.
  • the expandable sleeve is comprised of at least one flow reduction element 530 and a connecting tube 532.
  • the flow reduction element 530 can be formed using springs or polymer materials.
  • the flow reduction element 530 maybe formed from a spring and then covered with a flexible polymer to prevent partially digested food from entering the flow reduction element 530.
  • the flow reduction element 530 can be formed with a preset curved shape which can be straightened out for insertion with the aid of an endoscope.
  • the flow reduction element 530 diameter is sized to the small intestine diameter.
  • Figure 9b illustrates the connecting tube 532, anchoring member 520 and the flow reduction element 530 in a collapsed configuration for insertion into the small intestine. In this configuration the connecting tube 532 and the expandable sleeve 508 have been drawn toward the proximal end of the central shaft 506.
  • the connecting tube 532 also covers the collapsed anchoring member 520.
  • This movement of the connecting tube 532 relative to the central shaft 506 occurs because the flow reduction element 530 is collapsed in response to a force A applied to the connecting tube 532. It is anticipated that the connecting tube 532 can be pulled toward the proximal portion 502 of the central shaft to collapse the insert for insertion into the small intestine with the aid of an endoscope. Once in position, the force A is removed, the connecting tube 532 returns toward the distal portion 504 of the insert which releases the anchoring member 520 from its constraint and allows the expandable sleeve 508 to expand to its original diameter.
  • This invention has been described and specific examples of the invention have been portrayed. The use of those specifics is not intended to limit the invention in anyway. Additionally, to the extent that there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is my intent that this patent will cover those variations as well.

Abstract

Method and apparatus for treatment of morbid obesity by placement of a series of flow reduction elements (200) in the small intestine to induce satiety by slowing the emptying of the stomach are disclosed. Insert (20) has flow reduction elements (200) attached to an elongated tube (50) and are constructed from various shapes and configurations. The flow reduction elements (200) may be inflated with fluid or may be constructed from self-expandable materials. The device (20) is anchored in the antrum (7) of the stomach with an anchoring member (100) attached near a proximal end (52). The transoral gastric device (20) can be inserted with a delivery catheter through the working lumen of an endoscope or alongside an endoscope and may be removed with the aid of an endoscope if desired.

Description

METHOD AND APPARATUS FOR REDUCING OBESITY
Priority Information
This application claims priority to US Patent Application No. 10/999,410 filed on November 30, 2004, the entire contents of which are hereby expressly incorporated by reference.
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to the medical treatment of obesity in humans, and more particularly to apparatus and methods for curbing the appetite of persons being treated for obesity.
DESCRIPTIONOFTHERELATEDART
Extreme obesity is a major health concern in the United States and other countries. Its complications may include hypertension, diabetes, coronary artery disease, stroke, congestive heart failure, venous disease, multiple orthopedic problems and pulmonary insufficiency with markedly decreased life expectancy. Medical management including dietary, psychotherapy, medications and behavioral modification techniques have not yielded exceptional results in multiple trials. Despite the declaration of obesity as a major health problem, the Centers for Disease Control reports that obesity contributes to about 400,000 deaths annually, just behind tobacco (435,000) and ahead of alcohol (85,000), car accidents (43,000) and guns (29,000). Obesity and its complications now account for an estimated 9 percent of U.S. health spending.
Non-surgical approaches for the treatment of obesity include voluntary dieting which is often unsuccessful since most persons do not possess sufficient willpower to limit the intake of food. In addition to behavioral modification, several surgical techniques have been tried which induce malabsorption by reducing the absorptive surface of the small intestine or modify the stomach to reduce a patients desire to eat. Gastric reduction surgeries in which the stomach's volume is reduced had limited early success but often the stomach's size stretches over time so these patients did not exhibit real weight for a sustained period of time. Other surgical approaches combine gastric volume reduction by either partition or bypass with a reduction in the absorptive surface of the small intestine. These procedures may be both hazardous to perform in morbidly obese patients and often create numerous life- threatening postoperative complications. Such procedures typically are invasive, require a long recuperation time and subject the patient to undue pain and discomfort. Also, such operative procedures are often difficult to reverse. These procedures are also expensive and place a large burden on the national health care system.
Other endoscopic approaches include implantation of gastric balloons that prevent overeating by occupying volume within the stomach. This fills a portion of the stomach and provides the patient with a feeling of fullness, thereby reducing food intake. Many problems are associated with the gastric balloon device, including poor patient tolerance and complications due to rupture, migration, and pressure trauma to the gastrointestinal tract. Some sham-controlled studies have failed to show that the gastric balloon was superior to diet alone in achieving weight reduction.
Other devices are designed to attempt to limit the absorption of nutrients in the duodenum by funneling the food through a tube so that the digestive process bypasses portions of the small intestine entirely. By interrupting the intermixing of the digestive fluids and/or limiting the residence period within the stomach, it is believed that the food materials will not fully digest into particles small enough to be absorbed by the body. However these devices have not been evaluated clinically.
Having made the above critical observations, the present invention further recognizes a need for a transoral endoscopic device that mediates physiologic weight loss that is easily inserted into and removed from the gastrointestinal tract, well tolerated by the patient, does not migrate, does not adversely obstruct the lumen, and does not cause tissue injury. BRIEF SUMMARY OF THE INVENTION
The present invention provides a method and apparatus for treatment of morbid obesity by placement of a series of flow reduction elements in the small intestine to induce satiety. The flow reduction elements are attached along an elongated member which may or may not have a central lumen inside. This elongated member is used to position the flow reduction elements in the small intestine. The length and diameter of the flow reduction section can be selected by the physician to adjust the amount of weight reduction to the patients needs.
The central tube has an anchoring member attached near the proximal end that secures the proximal end in the antrum of the stomach. The anchoring member is sized so that it will not pass through the pyloric valve and so that it secures the central tube and the attached flow reduction elements in proper position in the small intestine. In one embodiment, the anchoring member is constructed of one or more inflatable balloons that when inflated are larger than the pylorus. The anchoring balloons can be deflated for delivery into the stomach and removed through the working lumen or alongside an endoscope. In another embodiment the anchoring member is an expandable umbrella-like skeleton frame that is attached to the flexible tube. The large end of the umbrella faces the pylorus and the frame can be collapsed for delivery and recovery.
The flow reduction elements can have various shapes and may be attached at various points along the central tube. The flow reduction elements may be inflated with fluid through a fluid connection with the central tube or may be constructed from self-expandable material such as a foam or spring structure. The space occupying flow reduction elements may also be filled or impregnated with pharmacologies, biochemicals, alimentary lipids, alimentary peptides or metabolic substances that release into the small intestine to further provide feelings of satiety.
The transoral gastric device can be inserted with a delivery catheter through the working lumen of an endoscope or alongside an endoscope and may be removed with the aid of an endoscope if desired. BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
FIG. 1 is a general drawing of the stomach and adjacent parts of the alimentary canal.
FIG. 2 is a perspective view of a duodenal/small intestinal insert in accordance with the present invention positioned inside the stomach and small intestine. FIG. 3 is a partial section view of a central tube illustrating attached flow reduction elements and central lumen.
FIG. 4 is a partial section view of a central tube illustrating eccentrically attached flow reduction elements and central lumen.
FIG. 5 is a perspective view of an alternative embodiment showing an elongated member and illustrating attached flow reduction elements.
FIG. 6 is a section view of the central tube inside of the pylorus and small intestine.
FIG 7 is a perspective section view of a central tube and an anchoring member.
FIG. 8 is a perspective view of an alternative embodiment of a central tube and an anchoring member. FIG. 9a is a section view of alternative embodiment of the current invention.
FIG. 9b is a section view of alternative embodiment of the current invention shown in a collapsed configuration.
DETAILED DESCREPTION OF THE INVENTION
Figure 1 shows the human stomach and small intestine. Important features are the esophagus 2, stomach 4, antrum 7, pylorus 8, pyloric valve 11, duodenum 10, jejunum 12 and ampulla of Vater 13. The esophagus 2 terminates at the nose or mouth at its superior end and at the stomach 4 at its inferior end. The stomach 4 encloses a chamber which is characterized, in part, by the esophageal-gastric juncture 6, which is an opening from the esophagus 2 at one end, and the antrum-pyloric juncture 5 which is a passageway between the antrum 7 through the pylorus 8 to the duodenum 10 at the other end. Specifically, the pylorus 8 controls discharge from the stomach 4 by a sphincter muscle, the pyloric valve 11, which enables the pylorus 8 to open wide enough to pass an object which is approximately one cubic centimeter or less. Gastric contents, after passing into the duodenum 10, continue on into the jejunum 12 and on into the ileum (not shown). The duodenum 10, jejunum 12 and ileum make up what is known as the small intestine. However these individual portions of the alimentary canal are sometimes individually referred to as the small intestine. In the context of this invention the small intestine refers to all or part of the duodenum, jejunum and ileum. The ampulla of Vater 13 is shown as a small protrusion on the medial wall. Bile and pancreatic fluids enter the duodenum 10 at this point to further aid digestion.
The duodenum 10 comprises the first nine to ten inches of the small intestine and is the only portion of the small intestine which is attached to the back wall of the abdominal cavity (retroperitoneum). The remainder of the small intestine is not attached to the body, but merely folds freely in a sack called the mesentery, which is contained within the peritoneum. The digestive process starts when food materials are mixed with saliva and enzymes in the mouth. The digestive process continues in the stomach 4, where the food is combined with acids and additional enzymes to liquefy the food. This food resides in the stomach 4, for a short time and then it passes into the duodenum 10 to be intermixed with bile and pancreatic juice, which make the nutrients contained therein available for absorption by the villi and microvilli of the small intestine or by other absorptive organs of the body.
The present invention understands that if the passage of partially digested food as described is partially blocked and the flow rate through the small intestine is reduced, then the emptying of the stomach and the duodenum will occur slower. This in turn will create a feeling of satiety and will decrease the consumption of food by an obese patient.
Additionally, because a large amount of the nutritional absorption occurs in the small intestine, if the amount of absorptive surface area of the walls of the small intestine is restricted or blocked, thus interrupting or reducing the intermixing of the digestive fluids, the partially digested food materials are not readily absorbed by the small intestine or other absorptive organs of the body. The partially digested food materials are then passed to the large intestine for elimination from the body with limited caloric absorption by the body. Furthermore, the present invention understands that if the physical characteristics of the device and/or a reduction of flow rate of food breakdown products through the small intestine results in distension of the small intestine, or increases the contact time between the small intestine and the partially digested food then this distention or increased contact time may activate osmoreceptors that may release hormones and neurotransmitters such as cholecystokinins (CCK) and neural signals that may induce satiety.
Figure 2 shows an exemplary non-limiting small intestinal insert 20 made in accordance with the present invention in position in the stomach and small intestine. The insert has a proximal portion 30 and a distal portion 40. The insert has a central tube 50 that extends between the proximal portion 30 and the distal portion 40. A series of flow reduction elements 200 can be attached to the distal portion of the central tube and may be sized to fit inside the small intestine. However the area of the central tube 50 near the ampulla of Vater 13 has no flow reduction elements 200 to prevent blockage of the ampulla of Vater. The central tube preferably has an anchoring member 100 attached near a proximal end 52 of the central tube 50, with the anchoring member 100 securing the proximal end 52 of the central tube 50 in the antrum 7 of the stomach. The anchoring member 100 is sized so that it will not pass through the pylorus 8, so that it can maintain the flow reduction elements 200 in proper position in the small intestine. In one embodiment, the anchoring member can be established by one or more inflatable balloons 102 that when inflated are larger than the pylorus 8. The inflatable balloons 102 can be deflated for delivery into the stomach and then inflated inside the stomach. The inflatable balloons 102 can also be later deflated for removal using endoscopic techniques.
Figure 3 shows the central tube 50 with the flow reduction elements 200 attached. The central tube 50 can be flexible and constructed of polymeric material that can be easily formed or extruded and delivered with the aid of an endoscope by known techniques. A central tube 50 that is soft and flexible will contour to the anatomy of the gastrointestinal tract and provide less irritation of the stomach lining. The central tube 50 can be made from polymers such as but not limited to nylon, polyolefins, polyurethane, silicone, polyvinyl chloride (PVC), Dacron®, latex, polyethylene, polypropylene, PVCD, polyethylene terephthalate (PET), teflon, and their mixtures and blocks or random copolymers . Further, the central tube may have a mono-layer, bi-layer or multi-layer construction. For instance, the central tube may have an inner layer of nylon or ethyl vinyl acetate and an outer layer of silicone for better biocompatibility. In addition, the substantially liquid-impermeable material could contain a radiopaque substance to enable visualization of the central tube in the patient's small intestine. Alternatively, the central tube could have band of radiopaque material like a metal foil around its circumference to enable visualization. The central tube polymer needs to be compatible with the chemical environment of the gastrointestinal tract and should provide enough structural integrity to prevent migration of the flow reduction elements in response to peristaltic action in the bowel. If desired, however, the central tube 50 can deploy to a fixed configuration so that once properly positioned it will maintain a steady position despite peristaltic movement of the stomach and small intestine. For example, the fixed configuration could be the shape that the duodenum 10 and jejunuml2 naturally assume in the abdomen.
The length of the central tube 50 can be established depending on the therapeutic result desired and the patient's anatomy. For example, the central tube 50 and the attached flow reduction elements 200 may extend into a portion of or through the entire duodenum 10. On some patients the central tube 50 and the attached flow reduction elements 200 may extend past the duodenum 10 and into the jejunum 12. It is anticipated that several lengths might be used by a physician to treat the various body types and metabolic demands. For example, if a patient is 20% overweight, the physician might select a length of central tube 50 with its attached flow reduction elements 200 that permits absorption of only 80% of the nutritional potential of a typical daily intake of calories. The reduction of caloric intake over time will lead to weight loss.
Figure 3 shows a central tube 50 with an outer wall 54 and an inner wall 56 that define an interior space 58. The interior space 58 forms an inner lumen 59 that may be continuous from the proximal end 52 to just short of the distal end 53 of the central tube 50. The distal end 53 of the central tube 50 is sealed at a point 55 so that fluid introduced into the central tube 50 does not leak out distally into the small intestine. In some embodiments a valve 90 can be located substantially at the proximal end of the inner lumen 59. The valve 90 may be a self sealing valve that has a septum 92 that can be accessed by a needle or blunt tip tube for introduction of fluid into the inner lumen 59. The valve 90 also can be accessed so that the fluid inside the inner lumen 59 of the central tube 50 can be aspirated for removal. It is to be understood that the valve type is not limited to a septum type valve only, and that other types of mechanical valves may also be used in place of the septum valve described.
As shown in Figure 3 and as mentioned above, one or more flow reduction elements 200 can be attached to the central tube 50. In some embodiments the diameter of each flow reduction element 200 can be concentric with the axis of the central tube 50. Each flow reduction element 200 has an outer wall 210, an inner wall 212, and an inner space 214 is established inside the inner wall 212. At or near its proximally-oriented surface 220 and also at or near its distally-oriented surface 222, each flow reduction element 200 can be attached to the central tube 50 with the inner space 214 of the flow reduction element 200 in fluid communication with the lumen 59 of the central tube 50, such that the inner space 214 surrounds the outer wall 54 of the central tube 50. Each flow reduction element 200 may be attached to the central tube 50 by adhesives, heat bonding, mechanical restraint or other suitable methods.
As shown in Figure 3, the central tube 50 can be formed with plural inlet/exit ports 216 that are located inside respective flow reduction elements 200. More specifically, each port 216 is formed completely through the central tube wall 51 to establish a pathway for fluid communication between the inner lumen 59 of the central tube 50 and the inner space 214 of the respective flow reduction element 200. Consequently, the inner lumen 59 of the central tube 50 may be used to introduce fluid into the inner spaces 214 of the flow reduction elements 200 and to inflate the flow reduction elements 200 from a collapsed configuration, in which insertion and removal of the flow reduction elements 200 is facilitated, to an inflated configuration shown in Figure 3, in which resistance to food passage is increased to induce satiety. Thus, the flow reduction element or elements 200 in this embodiment act as balloons that can be deflated and collapsed around the central tube 50 for introduction into the small intestine and then inflated to the desired diameter once in position.
Each flow reduction element or elements 200 can either be elastic balloons or inelastic balloons. The balloon may be a elastic balloon formed of latex, polyurethane, polyethylene, polypropylene, PVC, PVCD, polyethylene terephthalate (PET), teflon, their mixtures and blocks or random copolymers may also be used, for example. The material may be non-elastic or semi-elastic, such as Dacron®, Nylon®, and the like. It may alternatively be a inelastic balloon formed of polyethylene. Further, the balloon may have a mono-layer, bi-layer or multi-layer construction. For instance, the balloon may have an inner layer of nylon or ethyl vinyl acetate and an outer layer of silicone for better biocompatibility. In addition, the substantially liquid-impermeable material could contain a radiopaque substance to enable visualization of the balloon in the patient's small intestine. Alternatively, the central tube could have band of radiopaque material like a metal foil around its circumference to enable visualization. When an elastic balloon material is used to establish a flow reduction element 200, the flow reduction element 200 inflates to a diameter that is dependent on the volume of fluid introduced into the inner space of the flow reduction element. This embodiment permits adjustment of the balloon size as determined by the physician. If the balloon is too small, for instance, additional fluid could be introduced to enlarge the balloon diameter. Alternatively, if the balloon is too large, additional fluid could be removed to shrink the balloon diameter. It is understood that an alternate embodiment consisting of an inelastic balloon inflates to a diameter that is independent of the volume of fluid introduced into the inner space of the sphere. The diameter of this type of balloon is fixed when manufactured and does not permit in situ adjustment of the balloon size. However, this type of balloon prevents possible over inflation and rupture if too much fluid is introduced into the balloon.
The flow reduction elements 200 shown in Figure 3 have the shape of a round sphere. However, other shapes are contemplated and any shape that effectively functions to inhibit the passage of partially digested food into the small intestine is acceptable. It is understood that the ability of the small intestinal insert 20 to remain within the small intestine can be affected by the shape, orientation and tautness of the flow reduction elements 200. For example alternate shapes such as ovoid, elliptical, elongated ellipse and even irregular non- geometrical shapes are potentially feasible.
Figure 4 illustrates an alternative embodiment of the present invention in which one or more flow reduction elements 300 are eccentrically attached to a central tube 350. In this embodiment the axis or diameter of the flow reduction element or elements 300 is not concentric with the axis of the central tube. The outer wall 302 of the flow reduction element is attached to the side of an outer wall 354 of the central tube 350. An inner space 314 of each flow reduction element 300 is eccentric relative to the axis of the central tube 350 and is in fluid communication with an inner lumen 359 of the central tube 350 through a respective opening 316. As was the case with the embodiment shown in Figure 3, in the embodiment shown in Figure 4 the inner lumen 359 can be used to introduce and remove fluid into the inner space 314 of the flow reduction element 300 to move the flow reduction element 300 between inflated and collapsed configurations.
In this context the flow reduction elements 300 can be inflated with a fluid, either liquid or gas. Preferably the gas is air, nitrogen or carbon dioxide and the liquid is preferably water or water mixed with other solutions, such as sterile saline. It is important for the physician to monitor the flow reduction element 300 location in the small intestine and the diameter of the flow reduction element relative to the diameter of the small intestine. The flow reduction element can be inflated with a radiopaque fluid that is visible on X-ray. If the flow reduction element containing the radiopaque fluid is visible on x-ray, the physician can non-invasively visualize the flow reduction element size from outside the patient's body. This knowledge enables the physician to adjust the size of the flow reduction element by injecting additional fluid into the flow reduction element through the inner lumen 59 as required. Likewise radiopaque marker bands 218 as shown in Figure 4 can be placed around the central tubes 50 and 350 respectfully to facilitate visualization of the central tube's location in the small intestine. The radiopaque marker bands 218 can be placed at predetermined intervals so that the distance inside the small intestine can be used as depth markers and can be measured from outside the body, and can be created by tantulum impregnated ink, or tantulum bands.
Figure 5 shows an alternative embodiment with a central shaft 450 around λvhich first flow reduction elements 400 are concentrically attached and second flow reduction elements 410 are eccentrically attached. The element 400 can be attached to the central shaft 450 in any manner as described previously. The flow reduction elements 400 are made from material that can be folded or collapsed to a first volume suitable for insertion with the aid of an endoscope and then self expand to a second volume suitable for restricting the flow of partially digested food according to the present invention. The flow reduction elements can be made from materials such as sponge, foam, hydrogels or springs. The sponge can be composed of polyvinyl acetal polymer, neoprene, silicon, The foam can be composed of polyvinyl acetal polymer, The hydrogel can include any of the following: polysaccharides, proteins, polyphosphazenes, poly(oxyethylene)-poly(oxypropylene) block polymers, poly(oxyethylene)-poly(oxypropylene) block polymers of ethylene diamine, poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, polyvinyl acetate), and sulfonated polymers. These materials can be compacted into a small volume and then self expand to a pre-determined shape and volume when unrestricted. The central shaft 450 can be solid and without an inner lumen or inner space. Because the flow reduction elements self expand, the need for an inflation system is eliminated and this embodiment represents a simple mechanical design, flow reduction elements are attached mechanically, by heat fusing, adhesives or other suitable methods as known in the art.
The surface of the flow reduction element 415 and outside walls of the central tube 452 may be associated with slow release medicaments, enzymes, cofactors, pharmacologies, biochemicals, alimentary lipids, alimentary peptides or metabolic substances. In this context, "associated with" means filled or coated, covalently bonded, hydrogen-bonded, layered, impregnated, incorporated into matrices, and other such methods of associating molecules, which will be well-known to one of skill in the art. These substances are designed to release over time into the intestine to modify the biochemical processes or trigger alternative receptor sites that in turn will alter the digestive process. Pharmacologies of interest include, but are not limited to, lipase-inhibitors such as orlistat (Xenical®); oradrenergic/serotonergic agents such as sibutramine (Meridia®, Reductil®); anti-depressants such as fluoxetine (Prozac®) and sertraline (Zoloft®), bupropion, (Amfebutamone®, Wellbutrin® and Zyban®); noradrenergic agents/amphetamines such as diethylpropion (Tenuate®, Tepanil®), diethylpropion ER (Tenuate Dospan®), and phentermine (Adipex-P®, Fastin®, Obestin-30®, Phentamine®, Zantryl®; Lonamin®, Oby-Cap®); anti-epileptic drugs such as Topiramate® and Zonisamide®, sympathomimetic amines such as phendimetrazine tatrate (Bontril®), benzphetamine (Didrex®); and other drugs such as metformin (Glucophage®) and rimonabant, ephedrine, leptin, neuropeptide-Y receptor blockers.
Figure 6 shows the central tube 50 in the antrum 7, pylorus 8 and the duodenum 10; consisting of three parts, the duodenal bulb 1OA, the vertical duodenum 1OB, and the horizontal duodenum 1OC. The flow reduction elements have been removed from Figure 6 for clarity. The central tube 50 is shown traversing the pyloric valve 11. It is important that the diameter of the central tube not obstruct the pyloric valve opening so that the valve can still function normally. The central tube diameter should be in the range of 5 to 7 French. Distal to the pylorus 8 and immediately after entering the duodenum 10 the central tube 50 can assume a sharp bend of radius β between the duodenal bulb 1OA and the vertical duodenum 1OB , and a sharp bend of radius α between the vertical duodenum 1OB and horizontal duodenum 1OC. Preferably the radius β and the radius α may be between about 45° and about 110°. More preferably, the radius β and the radius α may be between about 60° and about 100° such that the central tube 50 bends to follow the inner lumen of the duodenum 10 at this these locations. It is advantageous that the central tube 50 be flexible enough to conform to this sharp angulation to avoid kinking. In another embodiment the central tube 50 can be pre-formed with a configuration that conforms to the duodenal angulations prior to insertion in the body and is constrained in a straight configuration by a stiffening rod 110 placed down the inner lumen 59 of the central tube 50 as shown. This stiffening rod 110 is placed into a separate lumen designed to house this stiffening rod or imbedded in the wall of the central tube 50. Upon insertion into the patient with the aid of an endoscope, when the central tube 50 reaches the location of the sharp bends in the duodenum 10, the stiffening rod 110 is withdrawn, thereby allowing the central tube 50 to assume the pre-formed shape. In another embodiment, the central tube 50 may have a shape memory alloy wire imbedded inside the central tube wall 51 or residing in the inner lumen 59. This shape memory alloy wire has a pre-set bend configuration with a radius β and a radius α that matches the bend configuration of the duodenum and is positioned in the central tube 50 at the corresponding location. Upon insertion into the patient with the aid of an endoscope, when the central tube 50 reaches the location of the sharp bend in the duodenum 10 and the shape memory alloy wire reaches a pre-set transition temperature equal to the temperature of the small intestine or 37° Fahrenheit, the wire assumes the programmed shape and forces the central tube 50 and the central tube wall 51 to assume the same shape. Shape memory alloy wire can be composed metal alloys, including but not limited to, NiTi (Nickel - Titanium), CuZnAl, and CuAlNi. In another embodiment, the central tube 50 may have a spring embedded inside the central tube wall 51 or inner lumen 59. This spring could be pre-shaped to the anatomy of the wall of the small intestine. The spring is held straight during delivery and conforms to the small intestine anatomy after release. The shape enables the device to remain in place.
Turning to various anchoring members 100 that can be used, as shown in Figure 7, the central tube 50 has an anchoring member 100 attached near the proximal end 52. The anchoring member 100 can be established by one or more inflatable balloons 102. These balloons 102 can be eccentrically attached to the central tube at point 104 near the proximal end 52 of the central tube 50. These balloons can be formed in many shapes and are not limited to the spherical shape shown. The central tube can be formed with an opening 116 for each respective balloon 102 so that a pathway for fluid communication is established between the inner lumen 59 of the central tube 50 and the inner space of each balloon 106. The inner lumen 59 is used to introduce fluid into the inner space of the balloon 106 and inflate the balloon 102 from a first volume in a collapsed state to a second volume or inflated state.
When the anchoring member 100 is fully inflated, it secures the proximal end of the central tube 52 in the antrum 7 of the stomach. The inflatable balloons 102 have a combined cross sectional diameter greater than the diameter of the pyloric valve 11 to prevent migration across the pylorus 8. The inflatable balloons 102 can be inflated and deflated by adding or removing fluid from the central tube inner lumen 59. The inflatable balloons 102 may be connected to the same central tube inner lumen 59 as flow reduction elements 200 and 300 as shown in Figures 3 and 4, and can be inflated simultaneously and deflated simultaneously. However, the central tube 50 may have more than one inner lumen so that the inflatable balloons 102 and individual flow reduction elements 200 and 300 may be inflated and deflated independently from each other.
Figure 8 illustrates another embodiment of the anchoring member 100 deployed in the antrum 7. A central tube 50 is attached to an inverted umbrella skeleton 160. This skeleton 160 has a ring 162 that surrounds the central tube 50 and is supported by three struts 164, 165 and 166. These struts are joined together at the central tube 50 at point 167 and attached to the ring 162 at points 170, 171 and 172. Although three struts are illustrated in Figure 8, it is possible to construct the anchoring member 100 with one or more struts. The ring 162 is made from flexible plastic material or flexible wire and has a diameter significantly larger than the diameter of the pyloric valve 11. The umbrella skeleton 160 is collapsed around the central tube 50 for insertion into the stomach with the aid of an endoscope. As the device is released from the endoscope, the umbrella skeleton 160 springs out and assumes a configuration shown in Figure 8. The struts 164, 165 and 166 may be made from plastic, metal or from plastic covered metal. The edge of the ring 162 which is in contact with the antrum walls 163, may be constructed to assist in securing the umbrella ring 162 to the walls of the antrum. The surface of the ring may be roughened to increase surface friction or the wall may have protrusions or barbs that physically attach to the stomach lining. Figure 9 illustrates another embodiment of the current invention. Figure 9a depicts a duodenal/small intestinal insert 500 with a proximal portion 502 and a distal portion 504 shown in an expanded state. In this embodiment, a central shaft 506 is attached to an expandable sleeve 508 at the sleeve distal end 510 near the distal portion 504 of the duodenal/small intestinal insert. The opposite end of the central shaft 506 is attached to a toroid anchoring member 520. The anchoring member 520 is attached at the central shaft 506 with two connecting struts 521 and 522. More than two connecting struts may be employed to securely attach the toroid anchoring member 520 to the central shaft 506. The anchoring member 520 is shaped like a funnel that is designed to seat in the Pylorus without obstructing its function. The central shaft 506 may be pre-formed to have a configuration that conforms to the anatomy of the duodenum 10 shown in Figure 6. A central shaft 506 so described would also force the expandable sleeve 508 to assume the configuration of the shaft 506. The central shaft 506 may be constructed out of wire, spring, shape memory alloys, hollow steel tubing or plastic polymers. The expandable sleeve is comprised of at least one flow reduction element 530 and a connecting tube 532. The flow reduction element 530 can be formed using springs or polymer materials. The flow reduction element 530 maybe formed from a spring and then covered with a flexible polymer to prevent partially digested food from entering the flow reduction element 530. The flow reduction element 530 can be formed with a preset curved shape which can be straightened out for insertion with the aid of an endoscope. The flow reduction element 530 diameter is sized to the small intestine diameter. Figure 9b illustrates the connecting tube 532, anchoring member 520 and the flow reduction element 530 in a collapsed configuration for insertion into the small intestine. In this configuration the connecting tube 532 and the expandable sleeve 508 have been drawn toward the proximal end of the central shaft 506. The connecting tube 532 also covers the collapsed anchoring member 520. This movement of the connecting tube 532 relative to the central shaft 506 occurs because the flow reduction element 530 is collapsed in response to a force A applied to the connecting tube 532. It is anticipated that the connecting tube 532 can be pulled toward the proximal portion 502 of the central shaft to collapse the insert for insertion into the small intestine with the aid of an endoscope. Once in position, the force A is removed, the connecting tube 532 returns toward the distal portion 504 of the insert which releases the anchoring member 520 from its constraint and allows the expandable sleeve 508 to expand to its original diameter. This invention has been described and specific examples of the invention have been portrayed. The use of those specifics is not intended to limit the invention in anyway. Additionally, to the extent that there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is my intent that this patent will cover those variations as well.

Claims

I claim the following:
1. A duodenal/small intestinal insert for treating obesity in a human patient comprising: an elongated member, said elongated member having a proximal end and a distal end; an anchoring member engaged with said elongated member at the proximal end; and at least one flow reduction element engaged with said elongated member.
2. A duodenal/small intestinal insert of claim 1, wherein a portion of the elongated member is rigid.
3. A duodenal/small intestinal insert of claim 1 , wherein a portion of the elongated member is flexible.
4. A duodenal/small intestinal insert of claim 1, wherein the elongated member is formed from shape memory materials.
5. A duodenal/small intestinal insert of claim 1, wherein the elongated member contains shape memory materials.
6. A duodenal/small intestinal insert of claim 1, wherein the elongated member is formed from a spring material.
7. A duodenal/small intestinal insert of claim 1, wherein the flow reduction element is concentric with the elongated member.
8. A duodenal/small intestinal insert of claim 1 , wherein the flow reduction element is eccentric to the elongated member.
9. A duodenal/small intestinal insert of claim 1, wherein the elongated member is a tube with a inner lumen.
10. A duodenal/small intestinal insert of claim 9, wherein the flow reduction element and/or anchoring member can be inflated from a first volume to a second volume with a fluid introduced into the inner lumen of the elongated member at the proximal end.
11. A duodenal/small intestinal insert of claim 10, wherein the fluid is a gas.
12. A duodenal/small intestinal insert of claim 1, wherein the flow reduction element is capable of expanding to about 30 to about 80 % of the small intestine diameter of the human patient.
13. A duodenal/small intestinal insert of claim 1, wherein the flow reduction element is capable of expanding to about 40 to about 60 % of the small intestine diameter of the human patient.
14. A duodenal/small intestinal insert of claim 1, wherein the flow reduction element is capable of expanding to a size to restrict but not occlude the movement of digested food through the small intestine.
15. A duodenal/small intestinal insert of claim 1, wherein the flow reduction element comprises a spring.
16. A duodenal/small intestinal insert of claim 1, wherein the flow reduction element self- expands from a first volume to a second volume when unrestrained.
17. A duodenal/small intestinal insert of claim 16, wherein the flow reduction element comprises open or closed cell foam.
18. A duodenal/small intestinal insert of claim 17, wherein the flow reduction element is associated with pharmacologies, biochemicals, alimentary lipids, alimentary peptides or metabolic substances.
19. The duodenal/small intestinal insert of claim 18, wherein the pharmacologic is sibutramine, diethylpropion, phentermine or orlistat.
20. A duodenal/small intestinal insert of claim 18, wherein the pharmacologies, biochemicals, alimentary lipids, alimentary peptides or metabolic substances are formulated to be released into the small intestine over time.
21. A duodenal/small intestinal insert of claim 1, wherein the anchoring member is configured to reside in the antrum of the human patient and when fully deployed restrict distal migration of the elongated member through the small intestine of the human patient.
22. A duodenal/small intestinal insert of claim 21 wherein the anchoring member comprises two or more balloons eccentrically arranged on the proximal end of the elongated member.
23. A duodenal/small intestinal insert of claim 22, wherein the balloons are inflatable and are capable of being inflated to a combined diameter is larger than the opening of the pylorus.
24. A duodenal/small intestinal insert of claim 21, wherein the anchoring member comprises two or more volume occupying members that are capable of self-expanding from a first volume to a second volume when unrestrained and their combined diameter of the second volume is larger than the opening of the pylorus.
25 A duodenal/small intestinal insert of claim 21, wherein the anchoring member comprises: collapsible, umbrella cage with a closed end and an open end, said closed end connected to the proximal end of the elongated member, the open end oriented toward the distal end of the elongated member, and the open end of the umbrella cage is attached to a toroid.
26. The anchoring member of claim 25, wherein the umbrella cage is comprised of a shape memory material.
27. The anchoring member of claim 26, wherein the umbrella cage is comprised of an alloy ofMTi, CuZnAl or CuAlNi.
28. The anchoring member of claim 25, wherein, wherein the umbrella cage is constructed from a spring material.
29. A duodenal/small intestinal according to claim 10, wherein a self sealing valve is positioned at the proximal opening of the elongated member, said valve adapted to control the amount of fluid introduced or released from the inner lumen of said elongated member and the opening at the distal opening of the elongated member is sealed; and wherein the flow reduction member(s) and/or anchor member is capable of being expanded by the introduction of fluid into the inner lumen of the elongated member.
30. A duodenal/small intestinal insert of claim 1, wherein the elongated member is flexible and is capable of conforming to the angulations of the duodenum and the small intestine of the human patient.
31. A duodenal/small intestinal insert of claim 1, wherein the elongated member is formed with a configuration that conforms to the angulations of the duodenum of the human patient.
32. The intestinal insert described in claim 31 wherein the elongated member is capable of being straightened for introduction into the duodenum and then capable of returning to the configuration that conforms to the angulations of the duodenum.
33. A method for treating obesity in a human patient, comprising: providing to the human patient the insert of claim 10, advancing the elongated member into the patient until the anchoring member is disposed in the stomach and the flow reduction element is disposed in the small intestine; and injecting fluid into at least one central lumen to expand the anchoring member and flow reduction element.
34. The method of claim 33, wherein the fluid is a gas.
35. The method of claim 33, wherein the flow reduction element is expanded to about 30 to about 80 % of the small intestine diameter of the human patient.
36. The method of claim 33, wherein the flow reduction element is expanded to about 40 to about
60 % of the small intestine diameter of the human patient.
37. The method of claim 33, wherein the flow reduction element is expanded to a size to restrict but not occlude the movement of digested food through the small intestine.
38. A method for treating obesity in a human patient, comprising: providing to a human patient the insert of claim 1 ; and collapsing at least one of the anchoring member, and the flow reduction element along a longitudinal axis of the elongated member by application of a collapsing force; advancing the elongated member into the patient until the anchoring member is disposed in the stomach and the flow reduction element is disposed in the small intestine; and releasing the collapsing force to cause at least one of the anchoring member, and the flow reduction element to return to its original shape and size.
39. A method for treating obesity in a human patient, comprising: providing to the patient the insert of claim 1 ; wherein the flow reduction element reduces the flow rate of partially digested food through the small intestine and maintains a volume of food in the stomach to produce a feeling of satiety.
40. A method for treating obesity in a human patient, comprising: providing to the human patient the insert of claim 1 ; wherein said flow reduction element reduces the flow rate of food through small intestine.
41. A method for treating obesity in a human patient, comprising the acts of: disposing at least one flow reduction element in the small intestine of the patient; disposing at least one anchoring member coupled to the flow reduction element in the . stomach of the patient, wherein the anchoring member cannot pass out of the stomach into the small intestine, thereby preventing migration of the flow reduction element out of the small intestine into the large intestine.
PCT/US2005/029932 2004-11-30 2005-08-22 Method and apparatus for reducing obesity WO2006060049A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL05791635T PL1817072T3 (en) 2004-11-30 2005-08-22 Apparatus for reducing obesity
CA2588901A CA2588901C (en) 2004-11-30 2005-08-22 Method and apparatus for reducing obesity
BRPI0518726-5A BRPI0518726A2 (en) 2004-11-30 2005-08-22 duodenum / small intestine insert to treat obesity in a human patient, anchor member, and method for treating obesity in a human patient
MX2007006419A MX2007006419A (en) 2004-11-30 2005-08-22 Method and apparatus for reducing obesity.
EP05791635A EP1817072B1 (en) 2004-11-30 2005-08-22 Apparatus for reducing obesity
JP2007544333A JP2008521550A (en) 2004-11-30 2005-08-22 Method and apparatus for reducing obesity
ES05791635T ES2416295T3 (en) 2004-11-30 2005-08-22 Apparatus to reduce obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/999,410 2004-11-30
US10/999,410 US7931693B2 (en) 2004-02-26 2004-11-30 Method and apparatus for reducing obesity

Publications (2)

Publication Number Publication Date
WO2006060049A2 true WO2006060049A2 (en) 2006-06-08
WO2006060049A3 WO2006060049A3 (en) 2009-04-23

Family

ID=36565470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/029932 WO2006060049A2 (en) 2004-11-30 2005-08-22 Method and apparatus for reducing obesity

Country Status (10)

Country Link
US (4) US7931693B2 (en)
EP (1) EP1817072B1 (en)
JP (1) JP2008521550A (en)
BR (1) BRPI0518726A2 (en)
CA (1) CA2588901C (en)
ES (1) ES2416295T3 (en)
MX (1) MX2007006419A (en)
PL (1) PL1817072T3 (en)
PT (1) PT1817072E (en)
WO (1) WO2006060049A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102917666A (en) * 2010-03-26 2013-02-06 Ibis医药股份有限公司 Intragastric implant devices
US8702642B2 (en) 2009-07-10 2014-04-22 Metamodix, Inc. External anchoring configurations for modular gastrointestinal prostheses
US9044300B2 (en) 2009-04-03 2015-06-02 Metamodix, Inc. Gastrointestinal prostheses
US9173734B2 (en) 2009-09-29 2015-11-03 IBIS Medical, Inc. Intragastric implant devices
US9173760B2 (en) 2009-04-03 2015-11-03 Metamodix, Inc. Delivery devices and methods for gastrointestinal implants
US9278019B2 (en) 2009-04-03 2016-03-08 Metamodix, Inc Anchors and methods for intestinal bypass sleeves
US9622897B1 (en) 2016-03-03 2017-04-18 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US10159699B2 (en) 2013-01-15 2018-12-25 Metamodix, Inc. System and method for affecting intestinal microbial flora
US10751209B2 (en) 2016-05-19 2020-08-25 Metamodix, Inc. Pyloric anchor retrieval tools and methods
US11090179B2 (en) 2008-10-10 2021-08-17 Peter Forsell Apparatus for treating GERD

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435094T3 (en) 2000-05-19 2013-12-18 C.R. Bard, Inc. Device and method of tissue capture and suturing
US7737109B2 (en) 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US7239912B2 (en) * 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US8845672B2 (en) 2002-05-09 2014-09-30 Reshape Medical, Inc. Balloon system and methods for treating obesity
US7025791B2 (en) 2002-12-02 2006-04-11 Gi Dynamics, Inc. Bariatric sleeve
CA2512203C (en) 2002-12-02 2012-10-23 Gi Dynamics, Inc. Bariatric sleeve
US7608114B2 (en) 2002-12-02 2009-10-27 Gi Dynamics, Inc. Bariatric sleeve
US7695446B2 (en) 2002-12-02 2010-04-13 Gi Dynamics, Inc. Methods of treatment using a bariatric sleeve
US7766973B2 (en) 2005-01-19 2010-08-03 Gi Dynamics, Inc. Eversion resistant sleeves
US8057420B2 (en) 2003-12-09 2011-11-15 Gi Dynamics, Inc. Gastrointestinal implant with drawstring
EP1708655A1 (en) 2003-12-09 2006-10-11 GI Dynamics, Inc. Apparatus to be anchored within the gastrointestinal tract and anchoring method
US8764725B2 (en) * 2004-02-09 2014-07-01 Covidien Lp Directional anchoring mechanism, method and applications thereof
US7931693B2 (en) * 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US8585771B2 (en) * 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
WO2005107641A2 (en) * 2004-05-03 2005-11-17 Fulfillium, Inc. Method and system for gastric volume control
WO2006016894A1 (en) 2004-07-09 2006-02-16 Gi Dynamics, Inc. Methods and devices for placing a gastrointestinal sleeve
AU2005287010B2 (en) 2004-09-17 2010-04-15 Gi Dynamics, Inc. Gastrointestinal anchor
US8070807B2 (en) 2004-11-19 2011-12-06 Fulfillium, Inc. Wireless breach detection
US9456915B2 (en) 2004-11-19 2016-10-04 Fulfilium, Inc. Methods, devices, and systems for obesity treatment
US8088132B2 (en) 2004-12-21 2012-01-03 Davol, Inc. (a C.R. Bard Company) Anastomotic outlet revision
US8403952B2 (en) * 2004-12-27 2013-03-26 Spatz-Fgia, Inc. Floating gastrointestinal anchor
US20060142731A1 (en) * 2004-12-27 2006-06-29 Jeffrey Brooks Floating gastro-intestinal anchor
WO2014082044A1 (en) 2012-11-26 2014-05-30 Spatz Fgia, Inc. System and methods for internalization of components of an adjustable intragastric balloon
US9974680B2 (en) 2004-12-27 2018-05-22 Spatz Fgia, Inc. System and methods for internalization of external components of adjustable intragastric balloon
US7771382B2 (en) 2005-01-19 2010-08-10 Gi Dynamics, Inc. Resistive anti-obesity devices
US7785291B2 (en) * 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7976488B2 (en) 2005-06-08 2011-07-12 Gi Dynamics, Inc. Gastrointestinal anchor compliance
WO2006135690A1 (en) 2005-06-10 2006-12-21 Wilson-Cook Medical Inc. Cautery catheter
US8216266B2 (en) * 2005-06-16 2012-07-10 Hively Robert L Gastric bariatric apparatus with selective inflation and safety features
FR2892296A1 (en) * 2005-10-21 2007-04-27 Christophe Bastid Intragastric balloon for e.g. man, has tubing with two canals and retrieved via endoscopic channel by using biopsy forceps, where canals of tubing have volume that is modified and tubing is reintroduced in stomach of patient
US20070100368A1 (en) 2005-10-31 2007-05-03 Quijano Rodolfo C Intragastric space filler
EP1948077B1 (en) * 2005-10-31 2015-12-23 ReShape Medical Corporation Intragastric space filler
US20070100369A1 (en) * 2005-10-31 2007-05-03 Cragg Andrew H Intragastric space filler
AU2006315262A1 (en) * 2005-11-10 2007-05-24 Sentinel Group, Llc Intragastric and transgastric device and method of visualization and therapeutic intervention
WO2007076021A2 (en) 2005-12-22 2007-07-05 Wilson-Cook Medical Inc. Intragastric bag for treating obesity
US8043206B2 (en) 2006-01-04 2011-10-25 Allergan, Inc. Self-regulating gastric band with pressure data processing
US7798954B2 (en) * 2006-01-04 2010-09-21 Allergan, Inc. Hydraulic gastric band with collapsible reservoir
US20070198039A1 (en) * 2006-01-27 2007-08-23 Wilson-Cook Medical, Inc. Intragastric device for treating obesity
JP2009531122A (en) 2006-03-28 2009-09-03 スパツフジア インコーポレイティド Floating gastrointestinal anchor
US9060835B2 (en) * 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
WO2007139920A2 (en) * 2006-05-26 2007-12-06 Endosphere, Inc. Improvements in methods and devices to curb appetite and/or reduce food intake
US7819836B2 (en) 2006-06-23 2010-10-26 Gi Dynamics, Inc. Resistive anti-obesity devices
US20080065136A1 (en) * 2006-08-30 2008-03-13 Andrew Young Distender device and method for treatment of obesity and metabolic and other diseases
US10350099B2 (en) 2006-09-01 2019-07-16 Ethicon Endo-Surgery, Inc. Devices and methods for anchoring an endoluminal sleeve in the GI tract
EP2572673B1 (en) * 2006-09-02 2015-08-19 Boston Scientific Scimed, Inc. Intestinal sleeves and associated deployment systems and methods
US8105392B2 (en) 2006-11-08 2012-01-31 Boston Scientific Scimed, Inc. Pyloric obesity valve
CA2675650A1 (en) * 2007-02-07 2008-08-14 Duocure, Inc. Duodenal stimulation devices and methods for the treatment of conditions relating to eating disorders
US8801647B2 (en) 2007-02-22 2014-08-12 Gi Dynamics, Inc. Use of a gastrointestinal sleeve to treat bariatric surgery fistulas and leaks
EP2134303A1 (en) * 2007-03-29 2009-12-23 Jaime Vargas Intragastric implant devices
US8226602B2 (en) * 2007-03-30 2012-07-24 Reshape Medical, Inc. Intragastric balloon system and therapeutic processes and products
US20100121371A1 (en) * 2007-04-30 2010-05-13 Spatz Fgia, Inc. Non-endoscopic insertion and removal of a device
US8007507B2 (en) 2007-05-10 2011-08-30 Cook Medical Technologies Llc Intragastric bag apparatus and method of delivery for treating obesity
US8142469B2 (en) 2007-06-25 2012-03-27 Reshape Medical, Inc. Gastric space filler device, delivery system, and related methods
CA2693259C (en) * 2007-07-16 2018-04-17 Kenneth F. Binmoeller A conformationally-stabilized intraluminal device for medical applications
US20110137227A1 (en) 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
US7883524B2 (en) 2007-12-21 2011-02-08 Wilson-Cook Medical Inc. Method of delivering an intragastric device for treating obesity
US8016851B2 (en) 2007-12-27 2011-09-13 Cook Medical Technologies Llc Delivery system and method of delivery for treating obesity
WO2009126331A1 (en) * 2008-04-09 2009-10-15 Endocore Llc Pyloric valve devices and methods
US8226593B2 (en) * 2008-04-09 2012-07-24 E2 Llc Pyloric valve
BRPI0915286A2 (en) 2008-07-02 2016-02-16 Endosphere Inc device adapted and configured for use within a mammalian duodenum, and method for adjusting the intake passage
US20100305397A1 (en) * 2008-10-06 2010-12-02 Allergan Medical Sarl Hydraulic-mechanical gastric band
BRPI0920512A2 (en) * 2008-10-10 2019-09-24 Milux Holding Sa apparatus for treating gastroesophageal reflux disease
US20100185049A1 (en) 2008-10-22 2010-07-22 Allergan, Inc. Dome and screw valves for remotely adjustable gastric banding systems
US9174031B2 (en) 2009-03-13 2015-11-03 Reshape Medical, Inc. Device and method for deflation and removal of implantable and inflatable devices
US8702641B2 (en) 2009-04-03 2014-04-22 Metamodix, Inc. Gastrointestinal prostheses having partial bypass configurations
US8911392B2 (en) 2009-04-08 2014-12-16 E2, Llc Systems and methods for treatment of obesity and type 2 diabetes
US8403877B2 (en) * 2009-07-01 2013-03-26 E2 Llc Systems and methods for treatment of obesity and type 2 diabetes
US8321030B2 (en) 2009-04-20 2012-11-27 Advanced Neuromodulation Systems, Inc. Esophageal activity modulated obesity therapy
EP2424464A4 (en) * 2009-04-30 2015-04-15 Svip 2 Llc Devices and methods for treating gastrointestinal and metabolic disorders
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
US8340772B2 (en) 2009-05-08 2012-12-25 Advanced Neuromodulation Systems, Inc. Brown adipose tissue utilization through neuromodulation
US8574184B2 (en) 2009-07-01 2013-11-05 E2 Llc Systems and methods for treatment of obesity and type 2 diabetes
US20110004234A1 (en) * 2009-07-01 2011-01-06 Endocore Llc Systems and Methods for Treatment of Obesity and Type 2 Diabetes
US8496608B2 (en) * 2009-07-01 2013-07-30 E2 Llc Systems and methods for treating obesity and type 2 diabetes
US8591452B2 (en) * 2009-07-01 2013-11-26 E2 Llc Systems and methods for treating obesity and type 2 diabetes
US20110004236A1 (en) * 2009-07-01 2011-01-06 E2 Llc Systems and Methods for Treating Obesity and Type 2 Diabetes
US9295574B2 (en) 2009-07-01 2016-03-29 E2, Llc Systems and methods for treating obesity and type 2 diabetes
US20110004146A1 (en) * 2009-07-01 2011-01-06 E2 Llc Systems and Methods for Treating of Obesity and Type 2 Diabetes
WO2011011629A2 (en) 2009-07-22 2011-01-27 Reshape Medical, Inc. Retrieval mechanisms for implantable medical devices
US9604038B2 (en) 2009-07-23 2017-03-28 Reshape Medical, Inc. Inflation and deflation mechanisms for inflatable medical devices
WO2011011743A2 (en) 2009-07-23 2011-01-27 Reshape Medical, Inc. Deflation and removal of implantable medical devices
US20110092998A1 (en) * 2009-10-13 2011-04-21 Spatz Fgia, Inc. Balloon hydraulic and gaseous expansion system
WO2011049651A1 (en) 2009-10-21 2011-04-28 Innovelle, Llc Bariatric device and method for weight loss
WO2011088381A1 (en) * 2010-01-14 2011-07-21 Pavilion Medical Innovations Systems and methods for bariatric therapy
US8636683B2 (en) * 2010-01-14 2014-01-28 Pavilion Medical Innovations, Llc Systems and methods for bariatric therapy
EP2533846B1 (en) 2010-02-08 2018-08-22 ReShape Medical LLC Materials and methods for improved intragastric balloon devices
US9622896B2 (en) 2010-02-08 2017-04-18 Reshape Medical, Inc. Enhanced aspiration processes and mechanisms for instragastric devices
US8678993B2 (en) 2010-02-12 2014-03-25 Apollo Endosurgery, Inc. Remotely adjustable gastric banding system
US8764624B2 (en) 2010-02-25 2014-07-01 Apollo Endosurgery, Inc. Inductively powered remotely adjustable gastric banding system
WO2011106637A1 (en) 2010-02-25 2011-09-01 Reshape Medical, Inc. Improved and enhanced explant processes and mechanisms for intragastric devices
US8840541B2 (en) * 2010-02-25 2014-09-23 Apollo Endosurgery, Inc. Pressure sensing gastric banding system
PL2547286T3 (en) 2010-03-15 2015-07-31 Apollo Endosurgery Inc Bariatric device and method for weight loss
WO2011127205A1 (en) 2010-04-06 2011-10-13 Reshape Medical , Inc. Inflation devices for intragastric devices with improved attachment and detachment and associated systems and methods
US9226840B2 (en) 2010-06-03 2016-01-05 Apollo Endosurgery, Inc. Magnetically coupled implantable pump system and method
US8517915B2 (en) 2010-06-10 2013-08-27 Allergan, Inc. Remotely adjustable gastric banding system
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) * 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2595693B1 (en) 2010-07-22 2015-03-04 Endobetix Ltd Pancreatiobiliary diversion device
US9211207B2 (en) 2010-08-18 2015-12-15 Apollo Endosurgery, Inc. Power regulated implant
US8698373B2 (en) 2010-08-18 2014-04-15 Apollo Endosurgery, Inc. Pare piezo power with energy recovery
US9233016B2 (en) 2010-10-18 2016-01-12 Apollo Endosurgery, Inc. Elevating stomach stimulation device
EP2629714B1 (en) 2010-10-18 2015-12-30 Apollo Endosurgery, Inc. Intragastric implants with duodenal anchors
US9463107B2 (en) 2010-10-18 2016-10-11 Apollo Endosurgery, Inc. Variable size intragastric implant devices
US8870966B2 (en) 2010-10-18 2014-10-28 Apollo Endosurgery, Inc. Intragastric balloon for treating obesity
WO2012054519A2 (en) 2010-10-18 2012-04-26 Allergan, Inc. Reactive intragastric implant devices
US9198790B2 (en) 2010-10-19 2015-12-01 Apollo Endosurgery, Inc. Upper stomach gastric implants
US8864840B2 (en) 2010-10-19 2014-10-21 Apollo Endosurgery, Inc. Intragastric implants with collapsible frames
US9095405B2 (en) 2010-10-19 2015-08-04 Apollo Endosurgery, Inc. Space-filling intragastric implants with fluid flow
US8920447B2 (en) 2010-10-19 2014-12-30 Apollo Endosurgery, Inc. Articulated gastric implant clip
US20120095483A1 (en) 2010-10-19 2012-04-19 Allergan, Inc. Anchored non-piercing duodenal sleeve and delivery systems
US9498365B2 (en) 2010-10-19 2016-11-22 Apollo Endosurgery, Inc. Intragastric implants with multiple fluid chambers
US9398969B2 (en) 2010-10-19 2016-07-26 Apollo Endosurgery, Inc. Upper stomach gastric implants
US8202291B1 (en) * 2011-01-21 2012-06-19 Obalon Therapeutics, Inc. Intragastric device
EP2773285B1 (en) * 2011-11-01 2018-12-26 Endosphere, Inc. Duodenal gastrointestinal devices
FR2983399B1 (en) * 2011-12-01 2014-12-05 Life Partners Europ INTRA-GASTRIC DEVICE WITH VARIABLE VOLUME
US8876694B2 (en) 2011-12-07 2014-11-04 Apollo Endosurgery, Inc. Tube connector with a guiding tip
US8979885B2 (en) 2012-02-24 2015-03-17 Elwha Llc Devices, systems, and methods to control stomach volume
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
CN104582645B (en) 2012-07-13 2017-04-05 Gi动力公司 TP grappling
US20140121646A1 (en) * 2012-10-29 2014-05-01 FABtec Medical, Inc. Nutrient Absorption Barrier And Delivery Method
US9265640B2 (en) 2013-08-28 2016-02-23 Ethicon Endo-Surgery, Inc. Conforming anchor for duodenal barrier
US9456917B2 (en) 2013-08-28 2016-10-04 Ethicon Endo-Surgery, Inc. Endoscopic transoral duodenal sleeve applier
WO2015085010A1 (en) * 2013-12-03 2015-06-11 IBIS Medical, Inc. Intragastric anchor devices and methods of delivery
KR20160094397A (en) 2013-12-04 2016-08-09 오발론 테라퓨틱스 인코퍼레이티드 Systems and methods for locating and/or characterizing intragastric devices
AU2014358675B2 (en) 2013-12-05 2019-10-03 Epitomee Medical Ltd Retentive devices and systems for in-situ release of pharmaceutical active agents
US20150230510A1 (en) 2014-02-19 2015-08-20 Mcneil Nutritionals, Llc Ingestible nutritional dose forms for inducing satiety
US20170079822A1 (en) * 2014-03-20 2017-03-23 Mayo Foundation For Medical Education And Research Gastric recycling apparatus and methods for obesity treatment
US9895248B2 (en) 2014-10-09 2018-02-20 Obalon Therapeutics, Inc. Ultrasonic systems and methods for locating and/or characterizing intragastric devices
FR3044216A1 (en) * 2015-12-01 2017-06-02 Life Partners Europe INTRA-GASTRIC BALLOON WITH GASTRIC FLOW LIMITER, REALIZATION ASSEMBLY OF SUCH A BALLOON AND ASSOCIATED METHOD
US10335303B2 (en) 2015-12-07 2019-07-02 Obalon Therapeutics, Inc. Intragastric device
US9700449B1 (en) 2016-01-13 2017-07-11 Agt Inc. Implantable weight control device to promote early and prolonged satiety in a bariatric patient
US10350100B2 (en) 2016-04-12 2019-07-16 Obalon Therapeutics, Inc. System for detecting an intragastric balloon
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2018085079A1 (en) 2016-11-04 2018-05-11 Obalon Therapeutics, Inc. Pressure control system for intragastric device
WO2018111916A1 (en) 2016-12-12 2018-06-21 Gi Dynamics, Inc. Therapeutic methods involving gastrointestinal implants
US11464660B2 (en) 2016-12-23 2022-10-11 Ganz Brake, Llc Obesity treatment devices, systems, and methods
EP3558162A4 (en) 2016-12-23 2020-08-05 Ganz, Alexander S. Obesity treatment devices, systems, and methods
BR112019016422A2 (en) 2017-02-09 2020-04-07 Spatz FGIA Ltd check valve with gastrointestinal balloon docking station
US10327938B1 (en) 2018-05-23 2019-06-25 Allium Medical Solutions Ltd. Intestinal sleeve
WO2020210659A1 (en) * 2019-04-11 2020-10-15 Boston Scientific Scimed, Inc. Delivery systems for devices with unsupported structure
US20230117119A1 (en) * 2021-10-14 2023-04-20 Lean Medical Technologies, Inc. Obesity treatment device and method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820584A (en) 1997-08-28 1998-10-13 Crabb; Jerry A. Duodenal insert and method of use
US20030040804A1 (en) 2001-08-27 2003-02-27 Stack Richard S. Satiation devices and methods
WO2004041133A1 (en) 2002-11-01 2004-05-21 Valentx, Inc. Apparatus and methods for treatment of morbid obesity

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773502A (en) 1953-12-21 1956-12-11 Arthur L Kaslow Device for treating alimentary tract
US4057065A (en) * 1976-06-21 1977-11-08 Dow Corning Corporation Percutaneous gastrointestinal tube
US4133315A (en) 1976-12-27 1979-01-09 Berman Edward J Method and apparatus for reducing obesity
US4134405A (en) 1977-01-10 1979-01-16 Smit Julie A Catheter and intestine tube and method of using the same
US4315509A (en) 1977-01-10 1982-02-16 Smit Julie A Insertion and removal catheters and intestinal tubes for restricting absorption
WO1980000007A1 (en) 1978-06-02 1980-01-10 A Rockey Medical sleeve
US4899747A (en) 1981-12-10 1990-02-13 Garren Lloyd R Method and appartus for treating obesity
US4416267A (en) 1981-12-10 1983-11-22 Garren Lloyd R Method and apparatus for treating obesity
US4485805A (en) 1982-08-24 1984-12-04 Gunther Pacific Limited Of Hong Kong Weight loss device and method
US4648383A (en) 1985-01-11 1987-03-10 Angelchik Jean P Peroral apparatus for morbid obesity treatment
US4694827A (en) 1986-01-14 1987-09-22 Weiner Brian C Inflatable gastric device for treating obesity and method of using the same
WO1989000407A1 (en) 1987-07-21 1989-01-26 Thomas Vincent Taylor Apparatus for arrest of bleeding at a duodenal ulcer
GB8603099D0 (en) * 1986-02-07 1986-03-12 Blass K G Gastrointestinal module
JPS6415063A (en) 1987-07-10 1989-01-19 Terumo Corp Catheter tube
US5084061A (en) 1987-09-25 1992-01-28 Gau Fred C Intragastric balloon with improved valve locating means
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
DE4012642A1 (en) 1990-04-20 1991-10-24 Wolf Gmbh Richard Therapy or surgical instrument - has pre-shaped balloons of different sizes inflated via endoscope etc.
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
CA2048307C (en) 1990-08-14 1998-08-18 Rolf Gunther Method and apparatus for filtering blood in a blood vessel of a patient
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
US5234454A (en) 1991-08-05 1993-08-10 Akron City Hospital Percutaneous intragastric balloon catheter and method for controlling body weight therewith
US5259399A (en) 1992-03-02 1993-11-09 Alan Brown Device and method of causing weight loss using removable variable volume intragastric bladder
US5396880A (en) 1992-04-08 1995-03-14 Danek Medical, Inc. Endoscope for direct visualization of the spine and epidural space
US5322697A (en) 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
US5439476A (en) 1993-02-04 1995-08-08 Trigonon, Inc. Inflatable laparoscopic retractor
US6102922A (en) 1995-09-22 2000-08-15 Kirk Promotions Limited Surgical method and device for reducing the food intake of patient
US6849068B1 (en) 1997-03-06 2005-02-01 Medtronic Ave, Inc. Aspiration catheter
US6059812A (en) * 1997-03-21 2000-05-09 Schneider (Usa) Inc. Self-expanding medical device for centering radioactive treatment sources in body vessels
US5868141A (en) * 1997-05-14 1999-02-09 Ellias; Yakub A. Endoscopic stomach insert for treating obesity and method for use
FR2767135B1 (en) 1997-08-06 2002-07-12 Genset Sa LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF
ATE382309T1 (en) 1997-11-07 2008-01-15 Salviac Ltd EMBOLIC PROTECTION DEVICE
EP1051157B1 (en) 1998-01-30 2002-01-02 Scios Inc. Controlled release delivery of peptide or protein
RU2215542C2 (en) 1998-02-23 2003-11-10 Массачусетс Инститьют Оф Текнолоджи Biodecomposing polymers able recovery of form
DK1062278T3 (en) 1998-02-23 2006-09-25 Mnemoscience Gmbh Polymers with shape memory
US6306163B1 (en) 1998-08-04 2001-10-23 Advanced Cardiovascular Systems, Inc. Assembly for collecting emboli and method of use
US6264700B1 (en) 1998-08-27 2001-07-24 Endonetics, Inc. Prosthetic gastroesophageal valve
ATE254889T1 (en) 1998-08-31 2003-12-15 Wilson Cook Medical Inc ANTI-BACKFLOW ESPIROUS PROSTHESIS
US6338043B1 (en) * 1998-12-01 2002-01-08 Nielsen Media Research Method and apparatus for developing a package of media advertising spots
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
KR100642955B1 (en) * 1999-04-23 2006-11-10 알자 코포레이션 Releasable linkage and compositions containing same
AU5275600A (en) 1999-05-18 2000-12-05 Silhouette Medical Inc. Surgical weight control device
US20040122456A1 (en) 2002-12-11 2004-06-24 Saadat Vahid C. Methods and apparatus for gastric reduction
ATE410975T1 (en) 1999-08-27 2008-10-15 Ev3 Inc SLIDING VASCULAR FILTER
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
CN1606620A (en) 2000-01-28 2005-04-13 因菲米德治疗有限公司 Slow releasing protein polymer
ATE275986T1 (en) 2000-05-31 2004-10-15 Mnemoscience Gmbh MEMORY THERMOPLASTIC AND POLYMER NETWORKS FOR TISSUE CONSTRUCTION
US6540789B1 (en) * 2000-06-15 2003-04-01 Scimed Life Systems, Inc. Method for treating morbid obesity
US20020072780A1 (en) 2000-09-26 2002-06-13 Transneuronix, Inc. Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6579301B1 (en) 2000-11-17 2003-06-17 Syntheon, Llc Intragastric balloon device adapted to be repeatedly varied in volume without external assistance
DE60229263D1 (en) 2001-05-17 2008-11-20 Wilson Cook Medical Inc INTRAGASTRAL DEVICE FOR THE TREATMENT OF FAT
US20040219186A1 (en) 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US6740121B2 (en) 2001-11-09 2004-05-25 Boston Scientific Corporation Intragastric stent for duodenum bypass
US7335210B2 (en) 2002-04-03 2008-02-26 Julie Ann Smit Endoscope and tools for applying sealants and adhesives and intestinal lining for reducing food absorption
US8303625B2 (en) 2002-04-18 2012-11-06 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Biodegradable shape memory polymeric sutures
CA2485249A1 (en) 2002-05-09 2003-11-20 Thomas D. Egan Gastric bypass prosthesis
ATE349918T1 (en) 2002-07-01 2007-01-15 Unilever Nv COMPOSITION THAT CAUSES A FEELING OF SATISFACTION
EP1551498A1 (en) 2002-07-26 2005-07-13 Transneuronix, Inc. Improved process for electrostimulation treatment of morbid obesity
US6746460B2 (en) * 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US6981978B2 (en) * 2002-08-30 2006-01-03 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
US7524914B2 (en) 2002-10-11 2009-04-28 The University Of Connecticut Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
US9060844B2 (en) * 2002-11-01 2015-06-23 Valentx, Inc. Apparatus and methods for treatment of morbid obesity
US7794447B2 (en) 2002-11-01 2010-09-14 Valentx, Inc. Gastrointestinal sleeve device and methods for treatment of morbid obesity
US7037344B2 (en) 2002-11-01 2006-05-02 Valentx, Inc. Apparatus and methods for treatment of morbid obesity
US7837669B2 (en) 2002-11-01 2010-11-23 Valentx, Inc. Devices and methods for endolumenal gastrointestinal bypass
US7025791B2 (en) 2002-12-02 2006-04-11 Gi Dynamics, Inc. Bariatric sleeve
US7695446B2 (en) 2002-12-02 2010-04-13 Gi Dynamics, Inc. Methods of treatment using a bariatric sleeve
US7608114B2 (en) 2002-12-02 2009-10-27 Gi Dynamics, Inc. Bariatric sleeve
CA2512203C (en) 2002-12-02 2012-10-23 Gi Dynamics, Inc. Bariatric sleeve
US7037343B2 (en) 2002-12-23 2006-05-02 Python, Inc. Stomach prosthesis
US7220271B2 (en) 2003-01-30 2007-05-22 Ev3 Inc. Embolic filters having multiple layers and controlled pore size
BRPI0407682A (en) 2003-02-19 2006-03-01 Mnemoscience Gmbh self-expanding device for gastrointestinal or urugenital area
US7291160B2 (en) 2003-03-17 2007-11-06 Delegge Rebecca Intragastric catheter
FR2853829B1 (en) 2003-04-16 2005-07-08 Cie Euro Etude Rech Paroscopie INTRODUCTION KIT FOR AN INTRA-GASTRIC IMPLANT, CASE FOR INTRODUCING SUCH AN IMPLANT AND CORRESPONDING MANUFACTURING METHOD
BR0302240B8 (en) 2003-06-24 2013-02-19 semi-stationary balloon in the gastric antrum with anchor rod for weight loss induction in humans.
US8048169B2 (en) * 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
US6994095B2 (en) * 2003-07-28 2006-02-07 Medventure Associates Iv Pyloric valve corking device and method
US9498366B2 (en) 2003-07-28 2016-11-22 Baronova, Inc. Devices and methods for pyloric anchoring
US20090259236A2 (en) * 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
US20050055014A1 (en) 2003-08-04 2005-03-10 Coppeta Jonathan R. Methods for accelerated release of material from a reservoir device
US20050038415A1 (en) 2003-08-06 2005-02-17 Rohr William L. Method and apparatus for the treatment of obesity
US8133256B2 (en) 2003-10-02 2012-03-13 Lawrence Livermore National Security, Llc Shape memory polymer foams for endovascular therapies
US7054690B2 (en) 2003-10-22 2006-05-30 Intrapace, Inc. Gastrointestinal stimulation device
EP1682051B1 (en) 2003-10-23 2010-07-28 Proxy Biomedical Limited A gastric constriction apparatus
EP1708655A1 (en) 2003-12-09 2006-10-11 GI Dynamics, Inc. Apparatus to be anchored within the gastrointestinal tract and anchoring method
US8147561B2 (en) * 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US7931693B2 (en) 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US7803195B2 (en) 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US20050277975A1 (en) 2004-06-09 2005-12-15 Usgi Medical Corp. Methods and apparatus for creating a working space within a body lumen or cavity
AU2005287010B2 (en) 2004-09-17 2010-04-15 Gi Dynamics, Inc. Gastrointestinal anchor
CA2582929A1 (en) 2004-09-30 2006-04-06 Duocure, Inc. Device and method for treating weight disorders
JP4856082B2 (en) 2004-10-15 2012-01-18 ビーエフケイダブリュ・エルエルシー Obesity device
US20060086362A1 (en) 2004-10-22 2006-04-27 Stephen Solomon Intestinal ablation to limit food absorption
DE102005016103B4 (en) 2005-04-08 2014-10-09 Merit Medical Systems, Inc. Duodenumstent
US9060835B2 (en) 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US20070282418A1 (en) 2006-05-30 2007-12-06 Boston Scientific Scimed, Inc. Anti-obesity flow controller
WO2008001381A2 (en) 2006-06-29 2008-01-03 Slimedics, Ltd. Gastrointestinal prostheses
US20080065136A1 (en) 2006-08-30 2008-03-13 Andrew Young Distender device and method for treatment of obesity and metabolic and other diseases
US20110137227A1 (en) 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820584A (en) 1997-08-28 1998-10-13 Crabb; Jerry A. Duodenal insert and method of use
US20030040804A1 (en) 2001-08-27 2003-02-27 Stack Richard S. Satiation devices and methods
WO2004041133A1 (en) 2002-11-01 2004-05-21 Valentx, Inc. Apparatus and methods for treatment of morbid obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1817072A4

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090179B2 (en) 2008-10-10 2021-08-17 Peter Forsell Apparatus for treating GERD
US9962278B2 (en) 2009-04-03 2018-05-08 Metamodix, Inc. Modular gastrointestinal prostheses
US10322021B2 (en) 2009-04-03 2019-06-18 Metamodix, Inc. Delivery devices and methods for gastrointestinal implants
US9173760B2 (en) 2009-04-03 2015-11-03 Metamodix, Inc. Delivery devices and methods for gastrointestinal implants
US9278019B2 (en) 2009-04-03 2016-03-08 Metamodix, Inc Anchors and methods for intestinal bypass sleeves
US9044300B2 (en) 2009-04-03 2015-06-02 Metamodix, Inc. Gastrointestinal prostheses
US8702642B2 (en) 2009-07-10 2014-04-22 Metamodix, Inc. External anchoring configurations for modular gastrointestinal prostheses
US9173734B2 (en) 2009-09-29 2015-11-03 IBIS Medical, Inc. Intragastric implant devices
CN102917666A (en) * 2010-03-26 2013-02-06 Ibis医药股份有限公司 Intragastric implant devices
US10159699B2 (en) 2013-01-15 2018-12-25 Metamodix, Inc. System and method for affecting intestinal microbial flora
US11793839B2 (en) 2013-01-15 2023-10-24 Metamodix, Inc. System and method for affecting intestinal microbial flora
US20170252195A1 (en) 2016-03-03 2017-09-07 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US10729573B2 (en) 2016-03-03 2020-08-04 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US9622897B1 (en) 2016-03-03 2017-04-18 Metamodix, Inc. Pyloric anchors and methods for intestinal bypass sleeves
US10751209B2 (en) 2016-05-19 2020-08-25 Metamodix, Inc. Pyloric anchor retrieval tools and methods
US11666470B2 (en) 2016-05-19 2023-06-06 Metamodix, Inc Pyloric anchor retrieval tools and methods

Also Published As

Publication number Publication date
BRPI0518726A2 (en) 2008-12-02
US20140100513A1 (en) 2014-04-10
PT1817072E (en) 2013-07-04
EP1817072A4 (en) 2009-12-02
JP2008521550A (en) 2008-06-26
EP1817072A2 (en) 2007-08-15
US10369035B2 (en) 2019-08-06
ES2416295T3 (en) 2013-07-31
US8623095B2 (en) 2014-01-07
US20110190684A1 (en) 2011-08-04
CA2588901C (en) 2014-11-25
US20170181877A1 (en) 2017-06-29
WO2006060049A3 (en) 2009-04-23
EP1817072B1 (en) 2013-03-27
US7931693B2 (en) 2011-04-26
CA2588901A1 (en) 2006-06-08
MX2007006419A (en) 2008-03-11
PL1817072T3 (en) 2013-11-29
US20050192614A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
EP1817072B1 (en) Apparatus for reducing obesity
US11596538B2 (en) Intragastric device for treating obesity
US9539133B2 (en) Stomach-spanning gastric implants
US7794447B2 (en) Gastrointestinal sleeve device and methods for treatment of morbid obesity
AU2005231323B2 (en) Systems and methods for treating obesity
EP2629713B1 (en) Stomach-spanning gastric implants
JP4790212B2 (en) Device for treating patient obesity
EP2699199B1 (en) System for bariatric therapy
US20170312111A1 (en) Anchorless Intragastric Device For Treating Obesity
US20110040232A1 (en) Duodenal liner device
EP3197522B1 (en) Intragastric device for treating obesity
AU2003298801A1 (en) Bariatric sleeve
WO2005082296A1 (en) Gastric bypass and methods
EP3352712A1 (en) Intragastric device for treating obesity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2588901

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006419

Country of ref document: MX

Ref document number: 2007544333

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005791635

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005791635

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0518726

Country of ref document: BR